Another Canadian patent approval for Episurf Medical
Episurf Medical (NASDAQ: EPIS B) has received another Notice of Allowance from the The Canadian Intellectual Property Office (CIPO).
The patent, entitled “Method and node for manufacturing a surgical kit for cartilage repair”, covers the medical image segmentation process used for joint damage visualisation as well as for designing Episurf Medical’s individualised joint implants and surgical instruments.
"This patent covers important details of the segmentation process that Episurf Medical uses for 3D visualisation of joints and comprises a crucial part of the company’s imaging technology”, comments Katarina Flodström, COO, Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 3 July 2019.